GNFT
Genfit
Stock NASDAQ – Stock Market Prices, News & Analysis
Genfit est une société biopharmaceutique française spécialisée dans la recherche et le développement de thérapies pour les maladies métaboliques et inflammatoires, notamment la stéatohépatite non alcoolique (NASH).
Genfit
GNFT
Genfit est une société biopharmaceutique française spécialisée dans la recherche et le développement de thérapies pour les maladies métaboliques et inflammatoires, notamment la stéatohépatite non alcoolique (NASH).
Price history of Genfit
Price history of Genfit
Performance & Momentum
Genfit Reports Q3 2025 Results, Exits US Nasdaq
Genfit announced revenues of €39.2 million for the first nine months of 2025, including a €26.5 million payment linked to the approval of Iqirvo® (elafibranor) in three major European markets. Additionally, the company completed the voluntary delisting of its American Depositary Shares from Nasdaq, focusing its listing primarily on Euronext. This move likely aims to simplify the shareholder structure and concentrate on core operating markets, affecting liquidity in the US market but clarifying GNFT's trading profile.
Similar stocks to Genfit
Take control
of your investments
Track your portfolios, analyze your performance and receive personalized insights to invest with strategy.
- Real-time multi-portfolio tracking
- AI analysis of your positions
- Counter your cognitive biases
